Company Profile
The AI AND LIFE SCIENCES INSTITUTE (HONG KONG) is a biotechnology company driven by cutting-edge generative artificial intelligence. With our proprietary end-to-end AI system, we forge a strong connection between the realms of disease biology and medicinal chemistry. By harnessing state-of-the-art machine learning techniques such as deep generative models, we unearth novel therapeutic targets from real-world data and craft exceptionally innovative molecules to meet unmet clinical demands.
Platform
At AILSI, we integrate target identification, hit identification, and lead optimization into a robust artificial intelligence platform to expedite the generation of candidate drug molecules. Leveraging AILSI’s drug discovery platform, based on deep learning models, we can create a multitude of multi-target molecules to meet the crucial parameters required for successful entry into clinical development, thus accelerating the development process.
Pipeline
We are currently advancing a robust pipeline of drug candidates, all discovered in-house, to address large unmet medical needs in cancer and aging-related diseases. Our cutting-edge AI-technology enables a high level of scalability, offering the potential to expand our portfolio and platforms to the benefit of patients worldwide. We also partner with biotech and research institutes to push forward the frontiers of innovation in the life sciences.
Our Team
We come from leading universities, renowned research laboratories, and R&D departments of multinational pharmaceutical companies. Our team members are experts in innovative drug discovery, artificial intelligence model design, and protein engineering, and have over 10 years of training and practical experience in pertinent fields.